Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
Medtronic
Queensland Health
Fish and Richardson
Dow
US Army
Novartis
Baxter
Accenture
Teva

Generated: October 21, 2017

DrugPatentWatch Database Preview

Tipranavir - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for tipranavir and what is the scope of tipranavir patent protection?

Tipranavir
is the generic ingredient in one branded drug marketed by Boehringer Ingelheim and is included in two NDAs. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Tipranavir has one hundred and fifty-six patent family members in thirty-one countries and ten supplementary protection certificates in eight countries.

There are two drug master file entries for tipranavir. One supplier is listed for this compound.

Summary for Generic Name: tipranavir

US Patents:3
Tradenames:1
Applicants:1
NDAs:2
Drug Master File Entries: see list2
Suppliers / Packagers: see list1
Bulk Api Vendors: see list28
Clinical Trials: see list67
Patent Applications: see list4,709
Therapeutic Class:Antivirals
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:tipranavir at DailyMed

Pharmacology for Ingredient: tipranavir

Drug ClassProtease Inhibitor
Mechanism of ActionHIV Protease Inhibitors
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Boehringer Ingelheim
APTIVUS
tipranavir
CAPSULE;ORAL021814-001Jun 22, 2005RXYesYes► Subscribe► SubscribeY► Subscribe
Boehringer Ingelheim
APTIVUS
tipranavir
CAPSULE;ORAL021814-001Jun 22, 2005RXYesYes► Subscribe► SubscribeY► Subscribe
Boehringer Ingelheim
APTIVUS
tipranavir
CAPSULE;ORAL021814-001Jun 22, 2005RXYesYes► Subscribe► SubscribeY► Subscribe
Boehringer Ingelheim
APTIVUS
tipranavir
SOLUTION;ORAL022292-001Jun 23, 2008RXYesYes► Subscribe► SubscribeY► Subscribe
Boehringer Ingelheim
APTIVUS
tipranavir
SOLUTION;ORAL022292-001Jun 23, 2008RXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: tipranavir

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Boehringer Ingelheim
APTIVUS
tipranavir
CAPSULE;ORAL021814-001Jun 22, 2005► Subscribe► Subscribe
Boehringer Ingelheim
APTIVUS
tipranavir
SOLUTION;ORAL022292-001Jun 23, 2008► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: tipranavir

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,169,181 Compounds useful to treat retroviral infections► Subscribe
6,531,139 Self-emulsifying formulation for lipophilic compounds► Subscribe
6,121,313 Pharmaceutical composition in a form of self-emulsifying formulation for lipophilic compounds► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: tipranavir

Country Document Number Estimated Expiration
Czech Republic20000156► Subscribe
Germany69823663► Subscribe
New Zealand502569► Subscribe
New Zealand502567► Subscribe
Denmark0999838► Subscribe
Norway323425► Subscribe
Norway323773► Subscribe
China1749252► Subscribe
Poland191780► Subscribe
Netherlands300216► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: TIPRANAVIR

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0216Netherlands► Subscribe300216, 20150504, EXPIRES: 20200503
2005008Lithuania► SubscribePRODCT NAME: TIPRANAVIRUM; REGISTRATION NO/DATE: EU/1/05/315/001 20051025
0758327/01Switzerland► SubscribeFORMER REPRESENTANTIVE: E. BLUM AND CO. PATENTANWAELTE, CH
C0047France► SubscribePRODUCT NAME: TIPRANAVIR; REGISTRATION NO/DATE: EU/1/05/315/001 20051025
220Luxembourg► Subscribe91220, EXPIRES: 20200504
C/GB06/009United Kingdom► SubscribePRODUCT NAME: (R-(R*,R*))-N-(3-(1-(5,6-DIHYDRO-4-HYDROXY-2-OXO-6-(2-PHENYLETHYL)-6-PROPYL-2H-PYRAN-3-YL)PROPYL)PHENYL)-5-(TRIFLUOROMETHYL)-2-PYRIDINESULFONAMIDE OR A PHARMACEUTICAL SALT THEREOF = (TIPRANAVIR OR A PHARMACEUTICAL SALT THEREOF); REGISTERED: CH 57330 20050825; UK EU/1/05/315/001 20051025
2005 00052Denmark► Subscribe
00216Netherlands► SubscribePRODUCT NAME: TIPRANAVIR, DESGEWENST IN DE VORM VAN EEN; REGISTRATION NO/DATE: EU/1/05/315/001 20051025
2005008,C0758327Lithuania► SubscribePRODUCT NAME: TIPRANAVIRUM; REGISTRATION NO/DATE: EU/1/05/315/001 20051025
C034/2005Ireland► SubscribeSPC034/2005: 20061023, EXPIRES: 20200503
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Chubb
Federal Trade Commission
Cantor Fitzgerald
US Department of Justice
Accenture
Covington
Teva
Cerilliant
McKesson
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot